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ABSTRACT
Objectives: Peptide-15 (P-15) is an analogue of the cell binding domain of collagen. P-15 has been shown to facilitate 
physiological to process in a way similar to collagen, to serve as anchorage for cells, and to promote the binding, migration 
and differentiation of cells. However, how P-15 alters osteoblast activity to promote bone formation is poorly understood. 
To study the osteoinductive properties of peptide P-15, we analyzed the expression levels of bone related genes in human 
mesenchymal stem cells treated with this biomaterial. 
Material and methods: Using real time Reverse Transcription-Polymerase Chain Reaction the quantitative expression of 
specific genes, like transcriptional factors (RUNX2 and SP7), bone related genes (SPP1, COL1A1, COL3A1, BGLAP, ALPL, 
and FOSL1) and mesenchymal stem cells marker (ENG) were examined. 
Results: P-15 causes a considerable induction of osteoblast transcriptional factor like osterix (SP7) and of the bone related 
genes osteopontin (SPP1) and osteocalcin (BGLAP). In contrast the expression of endoglin (ENG) was markedly decreased 
in stem cells treated with P-15 respect to untreated cells, indicating the differentiation effect of this biomaterial on stem cells. 
Conclusion: The present study shows the effect of P-15 on mesenchymal stem cells in the early differentiation stages: P-15 is 
an inducer of osteogenesis on human stem cells as indicated by the activation of bone related markers SP7, SPP1 and BGLAP.
The results may allow a better understanding of the molecular mechanism of bone regeneration and as a model for comparing 
other materials with similar clinical effects.
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INTRODUCTION
Several studies have been involved in the identification 
of factors that could help in the regeneration of missing 
tissue [1]. One avenue of research has been the 
identification of the specific cell-binding domain of type 
I collagen [1]. Type I collagen represents approximately 
one third of the total body proteins. Collagen, moreover, 
is a major determinant of the architecture and tensile 
strength of the tissues, and it modulates cell proliferation, 
migration, differentiation, and specific gene expression 
[2]. P-15 is a highly conserved linear peptide with 
a 15-amino acid sequence identical to the sequence 
contained in the residues 766-780 of the alpha chain 
of type I collagen [1]. P-15 from DENTSPLY Friadent 
(CeraMed, Lakewood, CO, USA) is an analogue of the 
cell-binding domain of collagen [2]. P-15 competes for 
cell surface sites for attachment of collagen and, when 
immobilized on surfaces, it promotes adhesion of cells 
[3]. P-15 has been shown to facilitate physiological 
processes in a way similar to collagen, to facilitate the 
exchange of mechanical signals, and to promote cell 
differentiation [4-6].  Like  other  bone  augmentation 
materials, P-15 associated with anorganic-derived 
bone matrix (ABM), has been shown to be helpful in 
the treatment of periodontal defects, and sinus-lifting 
procedures [1,7-11].
  In previous studies a genome wide screening of 
osteoblast-like cell line (MG-63) following treatment 
with P-15 was performed by using cDNA microarray 
[12]. Several genes covering a broad range of functional 
activities, like signalling transduction, differentiation, 
apoptosis,  cell-cycle  regulation,  were  significantly 
up- or down-regulated [12]. Then the genetic effect 
of P-15 was studied in the same cell system at post-
transcriptional level, with microRNA microarray 
[13,14]. A miRNA that regulates the transduction of 
genes  related  to  bone  formation  (TFIP11),  skeletal 
development (HOXD13, AEBP1, SHOX EN1 COMP 
SUFU IGF1 MATN1) and cartilage remodelling (NOG) 
was identified.
  Because few reports analyze the effects of 
P-15 on stem cells [15] and none focus on the genetic 
effects, the expression of genes related to the osteoblast 
differentiation were analyzed using cultures of bone 
marrow derived human mesenchymal stem cells (BM-
hMSCs) treated with P-15 for seven days, in order to 
detect the early effects of the common path of BMPs on 
stem cells.
MATERIAL AND METHODS
The study was approved by the Ethics Committee of 
 
the Ferrara University.
Stem cell preparation
Bone marrow derived human mesenchymal stem cells 
(BM-hMSCs) were obtained from the three healthy 
adult volunteers. There were 2 males and 1 female 
(average age of volunteers was 45 years); experiments 
were done in duplicate.
  Bone Marrow collected in heparinized tubes, 
was diluted 1 : 3 with phosphate buffered saline 
(PBS) (Lonza, Basel, Switzerland) and layered over 
a Ficoll-Histopaque gradient (1.077 g/ml; Sigma, St. 
Louis, MO, USA). The low-density mononuclear 
cells were washed twice in PBS, counted and plated 
at 106/cm2 in cell culture flasks (BD Falcon, Bedford, 
MA, USA) in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Lonza, Basel, Switzerland) supplemented 
with 20% heat inactivated fetal bovine serum (FBS) 
(Lonza, Basel, Switzerland) and antibiotics (100 U/ml 
Penicillin,  100  μg/ml  Streptomycin)  (Sigma-Aldrich, 
Inc., St Louis, Mo, USA), and incubated at 37 °C in 
a humidified atmosphere with 5% CO2. After 1 week, 
the non-adherent cells were removed by replacing 
the medium supplemented with 10% FBS. When the 
cultures were near confluence (after 2 weeks) the cells 
were recovered, by treatment with 1X trypsin/EDTA 
solution (Sigma-Aldrich, Inc., St Louis, Mo, USA), for 
cytometric analysis and functional assays. BM-hMSCs 
were maintained and subcultured for up to 10-15 
passages. 
Immunofluorescence
Cells were washed with PBS for three times and fixed 
with cold methanol for 5 min at room temperature. After 
washing  with  PBS,  cells  were  blocked  with  bovine 
albumin 3% (Sigma-Aldrich, Inc., St Louis, Mo, USA) 
for 30 min at room temperature. The cells were incubated 
overnight sequentially at 4 °C with primary antibodies 
raised against CD105 1 : 200, mouse (BD Biosciences, 
San Jose, CA, USA), CD73 1 : 200, mouse (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), CD90 
1:200, mouse (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA), CD34 1 : 200, mouse (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA). 
They were washed with PBS and incubated for 1 
h at room temperature with secondary antibody 
conjugated-Rodamine goat anti-mouse 1:200 (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). 
Subsequently, cells were mounted with the Vectashield 
Mounting Medium with DAPI (Vector Laboratories, 
Inc., Burlingame, CA, USA) and observed under a 
fluorescence  microscope  (Eclipse  TE  2000-E,  Nikon   
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Instruments S.p.a., Florence, Italy).
Cell culture
BM-hMSCs at fourth passage were grown in medium 
(Alphamem-Sigma Aldrich, Inc., St Louis, Mo, USA) 
supplemented with 10% fetal calf serum, antibiotics 
(Penicillin 100 U/ml and Streptomycin 100 µg/
ml – Sigma-Aldrich, Inc., St Louis, Mo, USA) and 
amminoacids (L-Glutamine – Sigma-Aldrich, Inc., St 
Louis, Mo, USA). The cultures were maintained in a 
5% CO2 humidified atmosphere at 37 °C.
  For the assay, cells were collected and seeded 
at a density of 1 x 105 cells/ml into 9 cm2 (3ml) wells 
by using 0.1% trypsin, 0.02% EDTA in Ca++ - and Mg 
- free Eagle’s buffer for cell release. 
  One set of wells were added with P-15 at 
the  concentration  of  10  μl/ml. Another  set  of  wells 
containing untreated cells were used as control. The 
medium was changed every 3 days.
  After seven days, when cultures were 
subconfluent, cells were processed for RNA extraction.
RNA processing
Reverse transcription to cDNA was performed directly 
from cultured cell lysate using the TaqMAn Gene 
Expression Cells-to-Ct Kit (Ambion Inc., Austin, TX, 
USA), following manufacturer’s instructions. Briefly, 
cultured cells were lysed with lysis buffer and RNA 
released in this solution. Cell lysate were reverse 
transcribed to cDNA using the RT Enzyme Mix and 
appropriate RT buffer (Ambion Inc., Austin, TX, USA).
  Finally the cDNA was amplified by real time 
PCR using the included TaqMan Gene Expression 
Master  Mix  and  the  specific  assay  designed  for  the 
investigated genes.
Real time PCR
Expression  was  quantified  using  real  time  RT-PCR. 
The gene expression levels were normalized to the 
expression of the housekeeping gene RPL13A and were 
expressed as fold changes relative to the expression 
of the untreated BM-hMSCs. Quantification was done 
with the delta/delta calculation method [16].
  Forward and reverse primers and probes for 
the selected genes were designed using primer express 
software (Applied Biosystems, Foster City, CA, USA) 
and are listed in Table 1. 
  All PCR reactions were performed in a 20 
µl  volume  using  the  ABI  PRISM  7500  (Applied 
Biosystems, Foster City, CA, USA). Each reaction 
contained 10 µl 2X TaqMan universal PCR master 
mix (Applied Biosystems, Foster City, CA, USA), 
400 nM concentration of each primer and 200 nM of 
Gene 
symbol
Gene name Primer sequence (5’ > 3’) Probe sequence (5’ > 3’)
SPP1 osteopontin
F-GCCAGTTGCAGCCTTCTCA
R-AAAAGCAAATCACTGCAATTCTCA CCAAACGCCGACCAAGGAAAACTCAC
COL1A1 collagen type I alpha1 F-TAGGGTCTAGACATGTTCAGCTTTGT
R-GTGATTGGTGGGATGTCTTCGT
CCTCTTAGCGGCCACCGCCCT
RUNX2 runt-related 
transcription factor 2
F-TCTACCACCCCGCTGTCTTC
R-TGGCAGTGTCATCATCTGAAATG ACTGGGCTTCCTGCCATCACCGA
ALPL alkaline phosphatase
F-CCGTGGCAACTCTATCTTTGG
R-CAGGCCCATTGCCATACAG CCATGCTGAGTGACACAGACAAGAAGCC
COL3A1 collagen, type III, 
alpha 1
F-CCCACTATTATTTTGGCACAACAG
R-AACGGATCCTGAGTCACAGACA
ATGTTCCCATCTTGGTCAGTCCTATGCG
BGLAP osteocalcin F-CCCTCCTGCTTGGACACAAA
R-CACACTCCTCGCCCTATTGG CCTTTGCTGGACTCTGCACCGCTG
CD105 endoglin
F-TCATCACCACAGCGGAAAAA
R-GGTAGAGGCCCAGCTGGAA TGCACTGCCTCAACATGGACAGCCT
FOSL1 FOS-like antigen 1 F-CGCGAGCGGAACAAGCT
R-GCAGCCCAGATTTCTCATCTTC
ACTTCCTGCAGGCGGAGACTGACAAAC
SP7 osterix
F-ACTCACACCCGGGAGAAGAA
R-GGTGGTCGCTTCGGGTAAA TCACCTGCCTGCTCTTGCTCCAAGC
RPL13A ribosomal protein L13
F-AAAGCGGATGGTGGTTCCT
R-GCCCCAGATAGGCAAACTTTC
CTGCCCTCAAGGTCGTGCGTCTG
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the probe, and cDNA. The 
amplification  profile  was  initiated 
by 10 minute incubation at 95 °C, 
followed by two-step amplification 
of 15 seconds at 95 °C and 60 seconds 
at 60 °C for 40 cycles. All experiments 
were performed including non-
template controls to exclude reagents 
contamination. PCRs were performed 
with two biological replicates.
RESULTS
BM-hMSCs were characterized by 
immunofluorescence. The cell surfaces 
were positive for mesenchymal 
stem  cell  marker,  CD105,  CD90  and 
CD73  and  negative  for  markers  of 
haematopoietic origin, CD34 (Figure 1). 
  Transcriptional expressions 
of several osteoblast-related genes   
(RUNX2,  SP7,  SPP1,  COLIA1, 
COL3A1, BGLAP, ALPL and FOSL1) 
and mesenchymal stem cells marker 
Figure 1. BM-hMSCs with indirect immunofluorescence (Rodamine). Cultured cells were 
positive for the mesenchymal stem cell marker CD73 (A), CD90 (B), CD105 (C) and 
negative for the hematopoietic markers CD34 (D). Nuclei were stained with DAPI. Original 
magnification x40.
(ENG)  were  examined  after  7  days  of 
supplement treatment with P-15 (10 μl/ml). 
  Quantitative real time RT–PCR of 
SP7, SPP1, BGLAP showed a considerable   
induction after treatment with P-15. 
However, P-15 treatment did not affect the 
mRNA expression of RUNX2 and ALPL 
that were similarly in both treated and 
untreated BM-hMSCs. COL1A1, COL3A1 
and FOSL1 were decreased in the presence 
of P-15 at day 7 like the stem cell marker 
ENG (Figure 2).
DISCUSSION
In order to understand the action of P-15 on 
BM-hMSCs, changes in expression of bone 
related marker genes (RUNX2, SP7, SPP1, 
COLIA1, COL3A1, BGLAP, ALPL and 
Figure 2. Gene expression analysis of BM-hMSCs after 7 days of treatment with 
P-15.
FOSL1) and mesenchymal stem cells marker (ENG) 
were investigated by real time RT–PCR.
  Mesenchymal  stem  cells  are  defined  as  self-
renewable, multipotent progenitor cells with the ability 
to differentiate, under adequate stimuli, into several 
mesenchymal lineages, including osteoblasts [17].
  In present study, mesenchymal stem cells from 
human bone marrow were isolated and characterized 
by morphology and immunophenotype. Isolated 
BM-hMSCs  showed  fibroblast-like  morphology 
and were positive for MSC surface molecules 
(CD90,  CD105,  CD73)  and  negative  for  markers  of 
haematopoietic progenitors (CD34).
  Two  osteoblast-specific  genes,  SPP1  and 
BGLAP, that are generally expressed by osteoblast 
in the early stage of their differentiation [18], were 
up-regulate in treated BM-hMSCs. 
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finger transcription factor that regulates bone formation 
and osteoblast differentiation in vitro and in vivo 
and that is expressed in the early stage of osteogenic 
differentiation.
  ENG (CD105), a surface markers used to define 
a bone marrow stromal cell population capable of 
multilineage differentiation [19], was down-regulated 
in treated BM-hMSCs respect to control. There is an 
inverse correlation between CD105 expression and 
the differentiation status of MSC [20]. This gene is a 
receptor for TGF-β1 and -β3 [21] and modulates TGF-β 
signalling by interacting with related molecules, such as 
TGF-β1, -β3, BMP-2, -7, and activin A. It is speculated 
that  these  members  of  the  TFG-β  superfamily  are 
mediators of cell proliferation and differentiation and 
play regulatory roles in cartilage and bone formation 
[22]. The disappearance of the CD105 antigen during 
osteogenesis suggests that this protein, like others in 
the TFG-β superfamily, is involved in the regulation of 
osteogenesis [23].
  Expression of RUNX2 and ALPL didn’t 
have  significant  change  in  treated  cells  respect  to 
control  after  7  day  of  treatment  with  P-15.  RUNX2 
is  the  most  specific  osteoblast  transcription  factor 
and is a prerequisite for osteoblast differentiation and 
consequently mineralization. This result is comparable 
with data reported by Kim et al. [24]. They showed 
that there was no BMP-2-mediated up-regulation of 
RUNX2 mRNA expression at days 3 or 7, but BMP-
2 treatment induced a significant and time dependent 
increase in SP7 mRNA expression [24].
  Alkaline phosphatase regulates mineralization 
of bone matrix. Several studies demonstrated that the 
potency  of  individual  substances  to  induce  alkaline 
phosphatase varies in a species-dependent manner. 
Glucocorticoids such as dexamethasone are potent 
inducers in human and rat stromal cells, but they have 
no  effect  on  alkaline  phosphatase  activity  in  mouse 
stromal cells [25,26]. Instead bone morphogenetic 
proteins (BMPs) are potent inducers of osteogenesis 
in both mouse and rat bone marrow stromal cells [27]. 
However, Diefenderfer et al. [28] showed that BMP-
2 alone is a poor osteoblast inducer in human marrow 
derived stromal cells.
  P-15 also modulates the expression of FOSL1 
that encodes for Fra-1, a component of the dimeric 
transcription factor activator protein-1 (Ap-1), which is 
composed mainly of Fos (c-Fos, FosB, Fra-1 and Fra-2) 
and Jun proteins (c-Jun, JunB and JunD).
  AP-1 sites are present in the promoters of many 
developmentally regulated osteoblast genes, including 
alkaline phosphatase, collagen I, osteocalcin (OC).
  McCabe et al. [29] demonstrated that differential  
expression of Fos and Jun family members could play 
a role in the developmental regulation of bone-specific 
gene expression and, as a result, may be functionally 
significant for osteoblast differentiation.
  In our study FOSL1 was down-regulated, 
probably because cells were at early stage of 
differentiation. Kim et al. [30] studying the effect of 
a new anabolic agents that stimulate bone formation, 
found that this gene was activated in the late stage of 
differentiation, during the calcium deposition.
  P15 also modulates the expression of genes 
encoding for collagenic extracellular matrix proteins 
like collagen type 1α1 (COL1A1) and collagen type 3α1 
(COL3A1). COL1A1, and COL3A1 were considerably 
down expressed as compared to the control when 
exposed to P15, probably because this gene are activated 
in the late stage of differentiation and are related to 
extracellular matrix synthesis.
  The present study shows the effect of P-15 on 
BM-hMSCs in the early differentiation stages: P-15 
is an inducer of osteogenesis on human stem cells 
but RUNX2 is not immediately activated. Moreover, 
we  have  chosen  to  perform  the  experiment  after  7 
days in order to get information on the early stages of 
stimulation.
  More investigations with several different time 
points are needed in order to understand the molecular 
events related to P-15 action. This model is useful to 
investigate the effects of a variety of substances on stem 
cells.
CONCLUSIONS
The results obtained showed that P-15 participates in 
the initial process of differentiation of BM-hMSCs into 
osteoblasts, inducing expression of factors related to the 
differentiation like SP7, SPP1 and BGLAP.
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